Le Lézard
Classified in: Health
Subject: TRI

Dr. Dan Holtzclaw Develops and Publishes Minimally Invasive Technique for the Treatment of Iatrogenic Nerve Injuries Secondary to Dental Implant Treatment


AUSTIN, Texas, Oct. 17, 2018 /PRNewswire-PRWeb/ -- Dr. Dan Holtzclaw, Chief Clinical Officer of DIA Dental Implant Centers, has recently published a new technique documenting the use of placental based growth factors for the treatment of nerve injuries related to poor placement of dental implants. According to Dr. Holtzclaw, "At our DIA Dental Implant Center locations in Austin and San Antonio, we occasionally see patients that have experienced nerve damage following dental implant treatment by providers at other clinics. These patients are coming to us for help as their dentists have provided no options for the treatment of their nerve injury. Unfortunately, these patients are often left with life altering neurosensory deficits that affect daily activities such as speaking, kissing, shaving, and smiling. Utilizing my extensive background in placental growth factor research over the past 13 years, and existing published data from the medical field, I have developed and implemented a minimally invasive technique that has helped improve the nerve conditions for many of these patients."    

Dr. Dan Holtzclaw recently published this new technique for the treatment of nerve injuries related to the iatrogenic placement of dental implants in the September 2018 issue of the Journal of Implant & Advanced Clinical Dentistry (http://www.jiacd.com) and lectured about the technique at the recent 2018 annual meeting of the American Academy of Implant Dentistry in Dallas, Texas. Dr. Holtzclaw will be presenting additional lectures about this technique in New York City and Los Angeles, California.

About Dr. Dan Holtzclaw
Dr. Dan Holtzclaw is one of the world's leading experts on full arch and dental implant treatment, having successfully performed thousands of these procedures. Dr. Holtzclaw has published 50+ scientific articles related to dental implant treatment in numerous peer reviewed dental journals and has provided 150+ lectures regarding dental implant treatment at major dental conferences across the globe. Dr. Dan Holtzclaw has served as the Editor-In-Chief and on the Editorial Boards of multiple dental implant journals.

About DIA Dental Implant Centers
DIA Dental Implant Centers are owned and operated by licensed dentists and are part of a professional affiliation of implant practices operated by oral surgeons, periodontists, and restorative dentists. DIA dentists have an exclusive focus on dental implants. With locations in Austin and San Antonio, DIA Dental Implant Centers is one of the fastest growing full arch dental implant groups in the United States. DIA Dental Implant Centers were founded to provide dental implant patients the option of complete treatment at one location with a stable team of providers that treat patients as people, not numbers. The traditional model of dental implant treatment often involves referrals to multiple locations and the involvement of numerous dental providers with varying levels of training, qualifications, and experience. DIA Dental Implant Centers offer comprehensive dental implant care at one single location with a team of dental providers whose sole focus is dental implants.

 

SOURCE Dr. Dan Holtzclaw


These press releases may also interest you

at 08:35
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor...

at 08:35
Bio-Rad Laboratories, Inc. , a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice...

at 08:33
1MD Nutrition, a leading developer of physician-formulated, condition-specific nutritional supplements with key ingredients in therapeutically significant dosages from substantiated, human clinical trials, is now a "Proud Partner" of the...

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:19
Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), a global leader in contract development and manufacturing of oligonucleotides for the therapeutic market announced today that Tammy Cooper will be appointed President of...



News published on and distributed by: